© 2022 MJH Life Sciences and Drug Topics. All rights reserved.
© 2022 MJH Life Sciences™ and Drug Topics. All rights reserved.
GENERAL HOSPITAL CORPORATION
MASSACHUSETTS GENERAL HOSPITAL
55 FRUIT ST
Daniel S. Raccuia is a 2016 PharmD candidate at University of Connecticut School of Pharmacy, Storrs, Conn.
June 10, 2016
Rolapitant is a novel NK1 receptor antagonist that maintains >90% receptor binding up to five days after a single 180-mg dose.